{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:43:00Z","timestamp":1793320980598,"version":"4.5.0"},"reference-count":75,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>The androgen receptor (AR) pathway plays a fundamental role in the treatment of prostate cancer, from the localized stage to metastatic disease, even in castration-resistant prostate cancer (CRPC). Despite the significant benefit for the earlier use of second-generation AR pathway inhibitors (ARPI), treatment resistance is still emerging. A deeper understanding of the biology of ARPI resistance is crucial for developing new therapeutic targets. In this review, we will explore the biology of second-generation ARPI resistance and discuss the evolving landscape of third-generation ARPI and steroid hormone inhibitors, which are shaping the future of prostate cancer therapeutics. Targeting the biosynthesis of steroid precursors with CYP11A1 inhibition, inducing AR degradation with proteolysis-targeting chimera degraders or restoring ARPI sensitivity with EZH2 inhibitors are among the most advanced strategies in development. Alongside these new drugs, AR genomic alterations and particularly AR mutations emerge as a promising biomarker for patient selection. These innovative therapeutics help bring more personalized approaches to patients with prostate cancer, aiming to overcome resistance and improve patient outcomes.<\/jats:p>","DOI":"10.1177\/17588359251379416","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T12:38:16Z","timestamp":1759149496000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["The future of androgen receptor targeting in prostate cancer: third-generation inhibitors and beyond"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9706-3945","authenticated-orcid":false,"given":"Alice","family":"Bernard-Tessier","sequence":"first","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Villejuif, France, Paris-Saclay University, Kremlin-Bicetre, France"},{"name":"Department of Oncology, Institut Gustave Roussy, 114 rue Edouard Vaillant, Villejuif 94800, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Naoun","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Villejuif, France, Paris-Saclay University, Kremlin-Bicetre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenn","family":"Barraud","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Villejuif, France, Paris-Saclay University, Kremlin-Bicetre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Flippot","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Villejuif, France, Paris-Saclay University, Kremlin-Bicetre, France"},{"name":"Drug Development Department (DITEP), Gustave Roussy-Cancer Campus, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Pobel","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Villejuif, France, Paris-Saclay University, Kremlin-Bicetre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Rey","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Villejuif, France, Paris-Saclay University, Kremlin-Bicetre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Capucine","family":"Baldini","sequence":"additional","affiliation":[{"name":"Drug Development Department (DITEP), Gustave Roussy-Cancer Campus, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Massard","sequence":"additional","affiliation":[{"name":"Drug Development Department (DITEP), Gustave Roussy-Cancer Campus, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Patrikidou","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Villejuif, France, Paris-Saclay University, Kremlin-Bicetre, France"},{"name":"Drug Development Department (DITEP), Gustave Roussy-Cancer Campus, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Fuerea","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Villejuif, France, Paris-Saclay University, Kremlin-Bicetre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Di Palma","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Villejuif, France, Paris-Saclay University, Kremlin-Bicetre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albig\u00e8s","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Villejuif, France, Paris-Saclay University, Kremlin-Bicetre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Villejuif, France; Paris-Saclay University, Kremlin-Bicetre, France"},{"name":"Drug Development Department (DITEP), Gustave Roussy-Cancer Campus, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Villejuif, France, Paris-Saclay University, Kremlin-Bicetre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"e_1_3_4_2_2","first-page":"293","article-title":"Studies on prostatic cancer I The effect of castration, of estrogen and of androgen Injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins C","year":"1941","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer I The effect of castration, of estrogen and of androgen Injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293\u2013297.","journal-title":"Cancer Res"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm972"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature20788"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2815"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.001"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.02.015"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.02.018"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0765"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0919"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505253322101"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-194512260-00012"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpuro1237"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00433"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00438-4"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1621\/nrs.06008"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.05.026"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature11125"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2666"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.243"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.01.011"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601127"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.06.039"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3023"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.05.036"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx155"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2764"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315815"},{"key":"e_1_3_4_29_2","article-title":"Ethnic disparities in clinical trials for FDA-approved drugs in prostate cancer: A post\u2013COVID-19 era analysis (2020-2024)","volume":"43","author":"Bastos BR","year":"2025","unstructured":"Bastos BR, Schwartz MA, Gligich O, et al. Ethnic disparities in clinical trials for FDA-approved drugs in prostate cancer: A post\u2013COVID-19 era analysis (2020-2024). J Clin Oncol 2025; 43: 25\u201325.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1341"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.204"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.221"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0123-9"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0226"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.08.012"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2015.254"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0249"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(85)90003-3"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.11.012"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3736"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21860-7"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2279"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4045"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.04.008"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3006"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00491-z"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300171"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.159"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.5060"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrp.2022.101062"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.017"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.5011"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.09.005"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01202-6"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.177"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(22)00994-7"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2761"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85969-x"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-022-00545-z"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.580"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.99"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34512"},{"key":"e_1_3_4_63_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.5031","article-title":"First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and\/or enzalutamide (ENZ) and chemotherapy (CT)","volume":"39","author":"De Bono JS","year":"2021","unstructured":"De Bono JS, Cook N, Yu EY, et al. First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and\/or enzalutamide (ENZ) and chemotherapy (CT). J Clin Oncol 2021; 39: 5031\u20135031.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1090"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4049"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.145"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3508"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp270"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.11.035"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.07.035"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1684"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.5061"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30906-3"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44514-2"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.9827"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251379416","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251379416","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251379416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:33:25Z","timestamp":1777588405000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251379416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":75,"alternative-id":["10.1177\/17588359251379416"],"URL":"https:\/\/doi.org\/10.1177\/17588359251379416","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"17588359251379416"}}